Abstract: The present disclosure relates to materials and methods for spatially analyzing nucleic acids that have been fragmented with a transposase enzyme, alone or in combination with other types of analytes

Abstract: A target (50) having a specific nucleic acid sequence included in a sample is measured using a detection probe (10) that has a detection part having a nucleic acid sequence complementary to the nucleic acid sequence of the target (50), a label molecule A (20) having a nucleic acid sequence that is complementary to the nucleic acid sequence of the target (50) and different from the nucleic acid sequence of the detection part, and a label molecule B (30) having a nucleic acid sequence complementary to the nucleic acid sequence of the label molecule A (20), in which a fluorescent molecule is attached to either one of the label molecule A (20) and the label molecule B (30), and the label molecule A (20) and the label molecule B (30) bind to each other at at least two or more sites to form a branched structural body of the label molecule A (20) and the label molecule B (30).

Abstract: Testing the many hypotheses from genomics and systems biology experiments demands accurate and cost-effective gene and genome synthesis. Here we describe a microchip-based technology for multiplex gene synthesis. Pools of thousands of ‘construction’ oligonucleotides and tagged complementary ‘selection’ oligonucleotides are synthesized on photo-programmable microfluidic chips, released, amplified and selected by hybridization to reduce synthesis errors ninefold. A one-step polymerase assembly multiplexing reaction assembles these into multiple genes. This technology enabled us to synthesize all 21 genes that encode the proteins of the Escherichia coli 30S ribosomal subunit, and to optimize their translation efficiency in vitro through alteration of codon bias. This is a significant step towards the synthesis of ribosomes in vitro and should have utility for synthetic biology in general.

Abstract: Multivalent binding compositions including a particle-nucleotide conjugate having a plurality of copies of a nucleotide attached to the particle are described. The multivalent binding compositions allow one to localize detectable signals to active regions of biochemical interaction, e.g., sites of protein-protein interaction, protein-nucleic acid interaction, nucleic acid hybridization, or enzymatic reaction, and can be used to identify sites of base incorporation in elongating nucleic acid chains during polymerase reactions and to provide improved base discrimination for sequencing and array based applications.

Abstract: The present invention relates to the field of nucleic acid sequence replication including PCR. Specifically, the present invention relates to methods and compositions for amplifying one or more target sequences from one or more template sequences. In particular, the present invention provides novel primer designs to enhance specificity of PCR reactions. The present invention also provides methods and compositions to perform the selection of specific sequence sections using specific primers and the amplification of all selected sequence sections using a pair of common primers in a single reaction tube.

Abstract: Methods for enhancing specificity of an analyte binding moiety or probe oligonucleotide to an analyte are provided herein. For example, methods provided herein include blocking a capture binding domain, thereby preventing hybridization to the capture domain of the capture probe affixed to a substrate. Further methods include releasing the block from the capture binding domain, thereby allowing the capture binding domain to specifically bind to the capture domain of the capture probe on the substrate.

Abstract: The present disclosure is directed to methods for assessing the severity and progression of a SARS-CoV2 infection in a subject using cell-free DNA (cfDNA). The present disclosure is further directed to methods for assessing tissue damage as a result of SARS-CoV2 infection. In addition, the present disclosure provides methods for treating a SARS-CoV2 infection in a subject. Finally, the disclosure also provides methods for detecting a microbial co-infection of a subject suffering from a SARS-CoV2 infection.

Abstract: A polynucleotide, comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region set forth in SEQ ID NO: 2, 3, 4, 20, 51, 68, 144, 148, 152, 162, 164, or 167 in the expression regulatory region of human DUX4 gene is expected to be useful for treating or preventing facioscapulohumeral muscular dystrophy (FSHD).

Abstract: The present disclosure provides methods, systems, compositions, and kits for the high-throughput detection of multi-molecule biomarkers in a biological sample. The disclosed methods, systems, compositions, and kits utilize antibody-oligonucleotide tags to detect two or more molecules that are in close proximity.

Abstract: Diagnostic biomarkers for diagnosing immune suppression/dysfunction. The diagnostic biomarkers are genes and/or transcripts that are up or down regulated compared to normal expression when a subject has been stressed either mentally and/or physically. The invention also relates to a method of detecting compromised or suppressed immune response in a subject by comparing certain diagnostic biomarkers in the subject to a control set of diagnostic biomarkers.

Abstract: The present disclosure relates generally to compositions and methods for diagnosing or predicting autism spectrum disorder (ASD). The methods are based on the discovery that certain genes, such as SOD2, OXT, GPER, and ERR?, have different expression levels in CD34+ cells or MNCs in ASD patients as compared to individuals not having ASD. Once the ASD patient is identified or predicted, compositions and methods are also provided for preventing or treating the ASD.

Abstract: Provided herein are methods and systems for use in identifying a subject with inflammatory bowel disease based on certain criteria, including genetics or serological markers measured in a sample obtained from the subject. Also provided are methods and systems for treatment of the inflammatory bowel disease in the subject. The systems described herein may include polygenic risk score (PRS), which is useful for determining the relative risk of the subject as compared with a reference population.

Abstract: Methods, systems, and apparatus are provided for determining whether a nucleic acid sequence imbalance exists within a biological sample. One or more cutoff values for determining an imbalance of, for example, the ratio of the two sequences (or sets of sequences) are chosen. The cutoff value may be determined based at least in part on the percentage of fetal DNA in a sample, such as maternal plasma, containing a background of maternal nucleic acid sequences. The percentage of fetal DNA can be calculated from the same or different data used to determine the cutoff value, and can use a locus where the mother is homozygous and the fetus is heterozygous. The cutoff value may be determined using many different types of methods, such as sequential probability ratio testing (SPRT).

Abstract: Disclosed herein are compositions and methods for detecting BCL2L14/ETV6 gene fusions relating to cancer. Also disclosed herein are compositions and methods for diagnosing and treating cancers that include detecting a BCL2L14/ETV6 gene fusion.

Abstract: The present invention relates to a method for predicting the prognosis of abreast cancer patient and, more particularly, to a method for predicting the prognosis of breast cancer by combining immune-related genes. The present invention is applicable to all breast cancer patients regardless of the breast cancer molecular subtype, and in addition, if the immune-related gene combination is used to predict the prognosis of breast cancer, as provided in the present invention, it is possible to predict the prognosis of a breast cancer patient without information on proliferation genes.

Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods directed to a thyroid cancer-specific biomarker panel. In a specific embodiment, a methods for identifying at thyroid tumor/nodule as benign or malignant comprises the steps of (a) measuring expression, in a sample obtained from the patient, by real-time quantitative polymerase chain reaction (RT-PCR) of at least three splice variant markers of a panel comprising high mobility group AT-hook 2 (HMGA2), transcript variant 1; PLAG1 zine finger (PLAG1), transcript variant 1; kallikrein related peptidase 7 (KLK7), transcript variant 1; fibronectin type III domain containing 4 (FNDC4); and cadherin 3 (CDH3), transcript variant 1; and (b) identifying the tumor as benign or malignant based on the measured expression levels of the panel of splice variant markers as compared to a control.

Abstract: The present disclosure relates to cancer and more particularly, methods of treating and/or determining the responsiveness to treatment and/or prognosis of cancers, such as lung cancer and breast cancer.

Abstract: This invention relates to methods for selecting a treatment and optionally treating subjects with muscle-invasive bladder cancer based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

Abstract: The invention relates to a method of predicting a response of a prostate cancer subject to radiotherapy, comprising determining or receiving the result of a determination of a gene expression profile for each of two or more PDE4D7 correlated genes selected from the group consisting of: ABCC5, CUX2, KIAA1549, PDE4D, RAP1GAP2, SLC39A11, TDRD1, and VWA2, said gene expression profiles being determined in a biological sample obtained from the subject, and determining the 5 prediction of the radiotherapy response based on the gen expression profiles for the two or more PDE4D7 correlated genes.

Abstract: The present disclosure provides methods for treating or inhibiting the growth of a tumor, including selecting a patient with cancer, wherein the patient has a tumor with threshold levels of both tumor mutation burden and expression of major histocompatibility complex, and administering to the patient a therapeutically effective amount of programmed death 1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof). In some embodiments, the cancer is skin cancer, such as basal cell carcinoma or cutaneous squamous cell carcinoma.

Abstract: In some embodiments, the present inventions relates generally to compositions, methods and kits for use in discriminating sequence variation between different alleles. More specifically, in some embodiments, the present invention provides for compositions, methods and kits for quantitating rare (e.g., mutant) allelic variants, such as SNPs, or nucleotide (NT) insertions or deletions, in samples comprising abundant (e.g., wild type) allelic variants with high specificity and selectivity. In particular, in some embodiments, the invention relates to a highly selective method for mutation detection referred to as competitive allele-specific TaqMan PCR (“cast-PCR”).

Abstract: Provided herein, in certain aspects, are methods involving epigenetic signatures comprising features from any of a methylation profile, a nucleosome dynamics profile, or a fragmentation profile, or any combination thereof. In other aspects, the present disclosure is directed to methods involving an epigenetic signature (such as methods of determining an epigenetic signature, methods of discovering an epigenetic signature, methods of diagnosis, and methods and treatment), and system, kits, and components useful therefor.

Abstract: Disclosed herein are compositions and methods for isolating DNA, such as cell-free DNA (cfDNA). In some embodiments, the cell-free DNA is from a subject having or suspected of having cancer and/or the cell-free DNA comprises DNA produced by a tumor. In some embodiments, the DNA isolated by the method is captured using a sequence-variable target region set and an epigenetic target region set, wherein the sequence-variable target region set is captured with a greater capture yield than the epigenetic target region set. In some embodiments, captured cfDNA of the sequence-variable target region set is sequenced to a greater depth of sequencing than captured cfDNA of the epigenetic target region set.

Abstract: The diagnostic markers that provide novel diagnostic criteria to blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been searched, and the presence of immunoblastoid cytomorphology, 8q24 rearrangement, and MYC expression were established as novel markers for subtyping BPDCN. It has been further found that the inhibitors which directly or indirectly inhibit the expression, functions, or signaling pathways of MYC, such as BET bromodomain-selective inhibitors or aurora kinase inhibitors, are effective in MYC-positive BPDCN, and HDAC inhibitors or BCL2 family protein inhibitors are effective as therapeutic drugs for BPDCN.

Abstract: Methods of isolating cell free RNA from individual's bodily fluid and reliably obtain cell free RNA data are presented, preferably by use of high-stability portions and/or use of targeted small amplicons on the cell free RNA.

Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.

Abstract: The present invention provides a nucleic acid amplification based method for detecting a hypervirulent Clostridium difficile strain in a biological sample. The present invention is based on the use of oligonucleotide primers and probes specific to negative and positive markers in hypervirulent Clostridium difficile genome.

Abstract: A molecular marker of cadmium accumulation in rice improves cadmium accumulation in rice grains. The molecular marker of cadmium accumulation in rice includes a DNA fragment shown in the 8899129-9307609 region of rice chromosome 7, which is lcrf1 or lcrf2, lcrf1 is a DNA fragment shown in the 8899129-9307609 of rice chromosome 7, and the lcrf2 is the DNA fragment shown in SEQ ID No.1 in the sequence listing. The present invention finds that the molecular marker of cadmium accumulation in rice is related to the cadmium accumulation in rice grains, and the homozygous rice whose molecular marker of cadmium accumulation in rice is SEQ ID No. 1 in the sequence listing has the characteristics of low grain cadmium accumulation when planted in high cadmium polluted fields. Therefore, the DNA fragment can be introduced into other backgrounds by breeding methods such as hybridization and backcrossing.

Abstract: The present disclosure relates to methods of screening for gain of function mutations in non-coding regions of target genes. The target genes may be NPQ genes, including photosystem II subunit S (PsbS), zeaxanthin epoxidase (ZEP), and violaxanthin de-epoxidase (VDE). The present disclosure further relates to methods of improving commercial crop plants or crop seeds by introducing gain of function mutations in non-coding regions of target genes, and to improved commercial crop plants or crop seeds produced by the methods.

Abstract: The present disclosure relates to high-throughput detection of polyketides using genetically encoded biosensors,

Abstract: Described herein is novel, economical device for photodetection of presence of a target nucleic acid in a sample. Accordingly, the detection takes place based on difference in light intensities. The invention further describes the method and apparatus for detection of target nucleic acid using said device.

Abstract: A disease screening device (100) comprising a substrate (101) and a sonication chamber (102) formed on the substrate (101). The sonication chamber (102) is provided with an ultrasonic transducer (105) which generates ultrasonic waves to lyse cells in a sample fluid within the sonication chamber (102). The device (100) comprises a reagent chamber (111) formed on the substrate (101) for receiving a liquid PCR reagent. The device (100) comprises a controller (23) which controls the ultrasonic transducer (105) and a heating arrangement (128) which is provided on the substrate (101). The device (100) further comprises a detection apparatus which detects the presence of an infectious disease, such as COVID-19 disease.

Abstract: A method for preparing test solution for pathogen detection purpose, system, kit, detection primer and method are provided. The method of preparing a test solution includes lysing the sample to be tested with a lysis buffer to release the nucleic acids contained in the sample to obtain a lysis buffer containing nucleic acids and/or pathogen nucleic acids; extracting the lysis buffer containing nucleic acids through a nucleic acid extraction device to obtain an extract containing host nucleic acids and/or pathogen nucleic acids; preparing the test solution for pathogen detection purposes from the extract. A large volume of samples can be used in the present application and it greatly improves sensitivity and specificity of the assay.

Abstract: This disclosure provides a gene expression-based method for determining a virally-infected subject's risk of developing severe symptoms. In some embodiments, the method may comprise measuring the amount of RNA transcripts encoded by at least two genes in a sample of RNA obtained from the subject, to obtain gene expression data; and based on the gene expression data, providing a report indicating the subject's risk of developing severe symptoms. Kits and methods of treatment are also provided.

Abstract: The present invention provides a kit and method for isothermal rapid detection of a SARS-CoV-2 virus nucleic acid.

Abstract: Provided herein are methods and compositions for rapid, highly sensitive detection of SARS-CoV-2, the causative agent of the COVID-19 pandemic or other target nucleic acids. The methods are low-cost and can be implemented in a portable format that does not require elaborate biosafety precautions or sophisticated laboratory equipment.

Abstract: The present invention relates to the use of a condensate collector such as portable or stationary dehumidifier placed in a defined testing space or area and used as a readily available and affordable tool to collect airborne virus particles in collected condensate from the testing atmosphere in the defined testing space or area, wherein the collected condensate is analyzed for virus biomarkers to identify viruses, such as SARS-CoV-2 or mutants or variants thereof, in the testing atmosphere.

Abstract: Methods, systems, and kits described herein are for detecting and sequencing nucleic acids (e.g., RNA) in a wide range of samples such as samples with low concentrations of nucleic acid, samples with degraded nucleic acid, samples that would not otherwise be amenable to conventional sequencing or RNA detection methods, poor quality samples, high quality samples in which rare mutations are sought, formalin-fixed paraffin-embedded samples, blood samples, etc. The methods of the present invention may use paired, large panels of primers to amplify many short fragments that overlap between but not within each panel. Each panel's amplicon set may fill the gaps between those of the opposing panel, thereby providing complete gene or genomic coverage. A preliminary, multiplex amplification step amplifies target nucleic acid for all downstream reactions such as Sanger sequencing, cloning, and NGS.

Abstract: A coupling system of copper slag recycling and CO2 mineralization process based on industrial solid waste includes the following steps: obtaining copper slags, performing a slag forming treatment, obtaining reforming slags, obtaining sponge iron, coupling the reforming slag with a CO2 mineralization process based on industrial solid waste, and coupling the CO2 generated in the process of obtaining sponge iron with the CO2 mineralization process based on industrial solid waste. The system includes a slag forming treatment device, a secondary treatment device, a first coupling device, and a second coupling device. The coupling system couples the recycling of copper slag with the existing CO2 mineralization process based on industrial solid waste. Various production lines can be organically integrated in a green and clean manner for both reforming slag and flue gas.

Abstract: The invention relates to a process for producing low-nitrogen crude steel. This process includes melting directly reduced iron and/or scrap in a melting furnace with arc resistance heating to give a metallic melt and a slag. The metallic melt is removed from the melting furnace and used to charge a converter. The metallic melt is refined in the converter to give liquid crude steel. The liquid crude steel is tapped having a nitrogen content [N] of not more than 50 ppm, especially of not more than 30 ppm.

Abstract: The present disclosure provides a method of making non-grain oriented (NGO) electrical steel. The method includes tapping the liquid steel out of a primary steelmaking furnace. Deoxidizing the liquid steel before or after transferring the deoxidized liquid steel to a ladle metallurgy furnace. Removing sulfur at the ladle metallurgy furnace (LMF). Adding fluxes and deoxidizer to the ladle slag and/or skimming off ladle slag to prevent sulfur reversion. Transferring the liquid steel from the ladle metallurgy furnace to an RH degasser for carbon removal by blowing oxygen. Adding fluxes at the RH before oxygen blowing to fortify the bottom layer of the ladle slag to prevent sulfur reversion. The removal of oxygen and sulfur prior to transferring the liquid steel to the RH degasser facilitates nitrogen removal and prevents carbon pick up during the step of adding fluxes and arcing for sulfur removal if sulfur removal is carried out at the LMF after carbon removal at the RH degasser in the conventional process.

Abstract: A steel for forging mechanical parts including of the following elements 0.04%?C?0.28%; 1.2%?Mn?2.2%; 0.3%?Si?1.2%; 0.5%?Cr?1.5%; 0.01%?Ni?1%; 0%?S?0.06%; 0%?P?0.02%; 0%?N?0.015%; 0%?Al?0.1%; 0.03%?Mo?0.5%; 0%?Cu?0.5%; 0.04%?Nb?0.15%; 0.01%?Ti?0.1%; 0%?V?0.5%; 0.0015%?B?0.004%; the remainder composition being composed of iron and unavoidable impurities caused by processing, the microstructure of the steel having microstructure including in area fraction, 55% to 85% of Martensite, 20% to 45% of Auto-tempered Martensite, 0 to 10% Residual Austenite and, wherein cumulated amounts of Auto-tempered martensite and martensite is at least 90%.

Abstract: The invention relates to a 9Ni steel plate for ship LNG storage tank with high strength and low yield ratio. According to the mass percentage, the chemical constituents are C: 0.02-0.05%, Si: 0.10-0.30%, Mn: 0.50-0.80%, Ni: 8.90-9.50%, P: ?0.0070%, s: ?0.0020%, Cr: 0.10-0.25%, Alt: 0.010-0.035%, Nb: 0.010-0.020%, Ca: 0.0005-0.0030%, O: ?0.0012%, N: ?0.004%, H: ?0.00015%, and the balance is Fe and unavoidable impurity elements. The production process flow is: smelting in a converter or electric furnace->RH vacuum degassing->LF refining->RH high vacuum degassing->Ca Treatment->continuous casting->slab slow cooling treatment->slab surface cleaning->heating->rolling ->quenching->tempering. For the 9Ni steel, especially the 9Ni thin steel plate, the invention adopts the constituents design of low C, 9% Ni, addition of Nb and Cr.

Abstract: A method manufacturing a steel strip, including the subsequent steps of hot rolling the strip into a hot rolled strip, cold rolling the hot rolled strip and hot dip coating the cold rolled strip with a Zn based coating by leading the strip through a bath including molten zinc and wiping the strip after the coating using a gas knife having a knife slot from which a wiping gas is projected and the steel strip is cold rolled to a final cold rolled thickness of between 0.40 mm and 1.00 mm in a multi-stand cold rolling mill, and the coated steel sheet includes a steel substrate provided with a hot dip metal coating.

Abstract: This hot-rolled steel sheet has a predetermined chemical composition, in a microstructure, in terms of area%, residual austenite is less than 3.0%, ferrite is less than 15.0%, and pearlite is less than 5.0%, an E value that indicates periodicity of the microstructure is less than 10.7, and an I value that indicates uniformity of the microstructure is less than 1.020, a standard deviation of a Mn concentration is 0.60 mass% or less, and a tensile strength is 780 MPa or more.

Abstract: Provided is a powder for annealing separator that is used for a grain-oriented electrical steel sheet and enables obtainment of a grain-oriented electrical steel sheet having excellent magnetic properties as a result of favorable purification of impurities in steel. The powder for annealing separator contains magnesium oxide as a main component, and has a nitrogen gas permeability of 0.020 cm/s or more and 0.50 cm/s or less in a state of being applied between coiled steel sheets before start of secondary recrystallization.

Abstract: To provide a highly corrosion-resistant stainless steel component made of martensitic stainless steel achieving both high corrosion resistance and high hardness without containing ferrite at a surface layer portion. The highly corrosion-resistant stainless steel component is made of martensitic stainless steel containing, by weight, from 0.35 to 0.43% of C, 0.5% or less of Si, 0.5% or less of Mn, 0.04% or less of P, 0.04% or less of S, from 15 to 17% of Cr, from 0.1 to 0.3% of W, from 1.5 to 3.0% of Mo, from 0.001 to 0.005% of B, and from 0.12 to 0.18% of N, with the balance being Fe and an inevitable impurity. The matrix structure of the surface layer portion of the entire outer surface is a two-phase mixed structure containing retained austenite and martensite, and the surface hardness is HRC 57 or more.

Abstract: A 780 MPa-grade ultra-high reaming steel having high surface quality and high performance stability, and a manufacturing method therefor. The ultra-high reaming steel comprises the following components in percentage by weight: 0.03-0.08% of C, Si?0.2%, 0.5-2.0% of Mn, P?0.02%, S?0.003%, 0.01-0.08% of Al, N?0.004%, 0.05-0.20% of Ti, 0.1-0.5% of Mo, Mg?0.005%, O?0.0030%, and the remainder being Fe and other inevitable impurities.

Abstract: Provided is a continuous hot-dip galvanizing apparatus comprising: a vertical annealing furnace having heating, soaking zone, and cooling zones therein; and a hot-dip galvanizing line downstream of the cooling zone. The heating, soaking, and cooling zones each have, in its upper portion, at least one upper hearth roll and, in its lower portion, at least one lower hearth roll. The soaking zone has a first and second humidified gas supply ports to supply a humidified gas having a dew point of 10° C. to 30° C. to the soaking zone. The first and second humidified gas supply ports are 1.0 m to 5.0 m lower than the center of the lower and upper hearth rolls, respectively, and overlap the steel sheet. The first humidified gas supply port is provided only for an ascending pass and the second humidified gas supply port is provided only for a descending pass.

Abstract: A 980 MPa-grade full-bainite ultra-high hole expansion steel and a manufacturing method therefor. The hole expansion steel has the following chemical compositions in percentage by weight: 0.05-0.10% of C, Si?2.0%, 1.0-2.0% of Mn, P?0.02%, S?0.003%, 0.02-0.08% of Al, N?0.004%, 0.1-0.5% of Mo, 0.01-0.05% of Ti, O?0.0030%, the remainder being Fe, and other inevitable impurities. The ultra-high hole expansion steel in the present invention has yield strength ?800 MPa, tensile strength ?980 MPa, and a hole expansion rate up to 60% or more, and can be applied in the parts of chassis components such as a control arm and an auxiliary frame, which require high strength thinning and complex forming, of passenger vehicles.